Active substances (API)
Active substances acting on the central nervous system:
- Amino acid neurotransmitters
- Acetylcholine
- Monoamine structure neurotransmitters
- Neurotransmitters with different structures, neuromodulators, and neuropeptides
Active substances with psychotropic effects:
- First and second-generation antipsychotics
- Antidepressants:
– Non-selective serotonin and norepinephrine reuptake inhibitors
– Selective serotonin reuptake inhibitors (SSRI)
– Selective norepinephrine reuptake inhibitors (SNRI)
– Selective serotonin and norepinephrine reuptake inhibitors (SSNRI)
– Norepinephrine and dopamine reuptake inhibitors (NDRI)
– Serotonin reuptake inhibitors with additional receptor activity
– Monoamine oxidase inhibitors
- Anxiolytics
Active substances stimulating the central nervous system:
- Psychostimulants
- Analeptics
- Nootropics
Active substances with psychodysleptic effects:
- NMDA receptor antagonists
- GABA-A receptor agonists
- κ-opioid receptor agonists
- Cannabinoids
Active substances used in the therapy of neurodegenerative diseases:
- Parkinson’s disease
- Huntington’s disease
- Alzheimer’s disease
- Amyotrophic lateral sclerosis
- Multiple sclerosis
Active substances with sedative-hypnotic effects:
- Barbiturates
- Agonists of the benzodiazepine site of the GABA-A receptor
- Non-benzodiazepine agonists
- Agonists of melatonin receptors MT1 and MT2
- Orexin receptor antagonists OX1R and OX2R
Active substances with antiepileptic effects of the first, second, and third generation
Active substances with analgesic, antipyretic, and anti-inflammatory effects:
- Opioids
- Non-opioid substances with analgesic effects
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Analgesic and antipyretic substances without clear acidic character, devoid of anti-inflammatory action
Active substances used in the therapy of gout
Active substances affecting the autonomic nervous system:
- Skeletal muscle relaxants
- Antihistaminic substances
Active substances acting on the circulatory system and affecting blood clotting:
- Cardiac glycosides
- Phosphodiesterase inhibitors (PDE)
Active substances with antiarrhythmic effects
Substances used in ischemic heart disease
Substances lowering blood pressure
Substances used in disorders of peripheral and cerebral circulation
Substances reducing blood lipid levels (hypolipemic drugs)
Polyunsaturated fatty acids (PUFAs) and sitosterols (plant sterols)
Diuretic substances
Substances used in diseases of the respiratory system
Substances used in diseases of the gastrointestinal system
Hormones and substances affecting the functions of the endocrine system
Vitamins, both water-soluble and fat-soluble, in various physical and chemical forms
Substances acting on pathogenic microorganisms – antibiotics and others
Substances used in antitumor chemotherapy:
- Alkylating agents
- Platinum complex compounds
- Antimetabolites
- Antibiotics with antitumor activity
- Topoisomerase inhibitors
- Anthracycline antibiotics with antitumor activity
- Antimitotic substances
- Cytostatics with various structures and diverse mechanisms of action
- Hormones and antihormones
- Antitumor substances affecting the activity of cellular kinases
- Cell growth modulators affecting receptor tyrosine kinases
- Epidermal growth factor receptor (EGFR) inhibitors
- Small molecule EGFR inhibitors
- Angiogenesis inhibitors
- Tumor blood vessel growth regulators
- Inhibitors of vascular endothelial growth factor receptor (VEGFR)
- Small molecule VEGFR inhibitors
- Isoindole-1,3-dione derivatives with antiangiogenic activity
- Small molecule fibroblast growth factor receptor (FGFR) inhibitors
- Anaplastic lymphoma kinase (ALK) receptor kinase inhibitors
- Tropomyosin receptor kinase inhibitors
- FLT3 tyrosine kinase receptor inhibitors
- Cytoplasmic tyrosine kinase inhibitors
- Bcr-Abl kinase inhibitors
- Bruton’s tyrosine kinase (BTK) inhibitors
- Cytoplasmic serine-threonine kinase inhibitors
- RAF pathway inhibitors
- Mitogen-activated protein kinase (MEK) inhibitors
- mTOR kinase inhibitors
- Cyclin-dependent kinase (CDK 4/CDK 6) inhibitors
- Phosphatidylinositol 3-kinase (PI3K) inhibitors
- Proteasome inhibitors
- Poly(ADP-ribose) polymerase (PARP) inhibitors
- Substances with epigenetic activity
- DNA methyltransferase inhibitors
- Histone deacetylase inhibitors
- Substances used in immuno-oncological chemotherapy
- Immunostimulating substances
- Immunosuppressive cytostatics
- Antimetabolites
